华蟾素片联合紫杉醇与顺铂方案在晚期非小细胞肺癌治疗中的近期疗效  

The short-term efficacy of cinobufagin tablet combined with paclitaxel and cisplatin regimen in the treatment of advanced non-small cell lung cancer

作　　者：刘圣斌 倪璇 曾江辉 LIU Shengbin;NI Xuan;ZENG Jianghui(Department of Respiratory and Critical Care Medicine,The Second People's Hospital of Jingdezhen,Jingdezhen,Jiangxi,333000,China)

机构地区：[1]景德镇市第二人民医院呼吸与危重症医学科,江西景德镇333000

出　　处：《当代医学》2024年第23期11-15,共5页Contemporary Medicine

摘　　要：目的探讨华蟾素片联合紫杉醇^(+)顺铂(paclitaxel and cisplatin,TP)方案在晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)治疗中的近期疗效。方法选取2018年2月至2022年2月于景德镇市第二人民医院接受治疗的80例晚期NSCLC患者作为研究对象,根据随机抽签法分为华蟾素片^(+)TP组与TP组,每组40例。TP组给予TP方案化疗,华蟾素片^(+)TP组在TP基础上加用华蟾素片治疗。比较两组近期疗效、化疗前后卡氏功能状态(Karnofsky performance status,KPS)评分、血清肿瘤指标[细胞角蛋白19片段抗原21-1(cytokerantin 19 fragment antigen 21-1,CYFRA21-1)、糖类抗原125(carbohydrate antigen 125,CA125)]、免疫功能指标(CD3^(+)、CD4^(+)、CD8^(+))及不良反应发生情况。结果华蟾素片^(+)TP组客观缓解率为57.50%,疾病控制率为90.00%,均高于TP组的35.00%、72.50%,差异有统计学意义(P<0.05)。化疗1个月后,两组KPS评分均高于化疗前,且华蟾素^(+)TP组高于TP组,差异有统计学意义(P<0.05)。化疗1个月后,两组CYFRA21-1、CA125水平均低于化疗前,且华蟾素片^(+)TP组低于TP组,差异有统计学意义(P<0.05)。化疗1个月后,两组CD3^(+)、CD4^(+)水平均高于化疗前,CD8^(+)水平均低于化疗前,且华蟾素^(+)TP组CD3^(+)、CD4^(+)水平均高于TP组,差异有统计学意义(P<0.05),但两组间CD8^(+)水平比较差异无统计学意义。华蟾素片^(+)TP组骨髓抑制、肢体疼痛发生率均低于TP组,差异有统计学意义(P<0.05);两组胃肠道反应、肾功能损伤发生率比较差异无统计学意义。结论华蟾素片联合TP方案化疗晚期NSCLC患者近期疗效良好,可改善患者身体功能,增强机体免疫力,减少肿瘤标志物表达,预防骨髓抑制、肌肉疼痛等不良反应的发生。Objective To investigate the short-term efficacy of cinobufagin tablet combined with paclitaxel and cisplatin(TP)regimen in the treatment of advanced non-small cell lung cancer(NSCLC).Methods 80 patients with advanced NSCLC who received treatment in The Second People's Hospital of Jingdezhen from February 2018 to February 2022 were selected as research subjects,and they were divided into the cinobufagin tablet+TP group and TP group according to the sealed envelope lottery method,with 40 cases in each group.The TP group was treated with TP regimen chemotherapy,while the cinobufagin tablet+TP group was added with cinobufagin tablet on the basis of TP regimen.The short-term efficacy,Karnofsky performance status(KPS)score,serum tumor indicators(cytokeratin 19 fragment antigen 21-1[CYFRA21-1],carbohydrate antigen 125[CA125])and immune function indicators(CD3^(+),CD4^(+),CD8^(+))before and after chemotherapy and occurrence of adverse reactions were compared between the two groups.Results The objective remission rate and disease control rate in the cinobufagin tablet+TP group were 57.50%and 90.00%,respectively,which were higher than 35.00%and 72.50%in the TP group,and the differences were statistically significant(P<0.05).After 1 month of chemotherapy,the KPS score of the two groups was higher than that before chemotherapy,and the cinobufagin tablet+TP group was higher than the TP group,the difference was statistically significant(P<0.05).After 1 month of chemotherapy,the levels of CYFRA21-1 and CA125 of the two groups were lower than those before chemotherapy,and the cinobufagin tablet+TP group was lower than the TP group,and the differences were statistically significant(P<0.05).After 1 month of chemotherapy,the levels of CD3^(+)and CD4^(+)of the two groups were higher than those before chemotherapy,while the level of CD8^(+)was lower than that before chemotherapy,and the levels of CD3^(+)and CD4^(+)in the cinobufagin tablet+TP group were higher than those in the TP group,and the differences were statistically signifi

关 键 词：华蟾素片 紫杉醇 顺铂 晚期非小细胞肺癌 

分 类 号：R73[医药卫生—肿瘤]